The emerging understanding of molecular changes in a wide range of brain tumours has led to a significant shift in how these tumours are diagnosed, managed and treated. This article will provide a hands-on overview of the relevant biomarkers and their association with newly defined biological tumour entities.
Keywords: ATRX; Astrocytoma; BRAF; BRAF inhibitor; EGFR; Ependymoma; Glioblastoma; Histone; IDH; MGMT; Mutation; Oligodendroglioma; TERT; Temozolomide; Tumour heterogeneity.